Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Public ClinicalTrials.gov record NCT02211131. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Study identification
- NCT ID
- NCT02211131
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 150 participants
Conditions and interventions
Interventions
- Immediate surgical resection of melanoma lesion(s) Procedure
- Talimogene Laherparepvec Drug
Procedure · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2015
- Primary completion
- Apr 29, 2019
- Completion
- Apr 27, 2022
- Last update posted
- Jun 4, 2023
2015 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35249 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Daytona Beach | Florida | 32117 | — |
| Research Site | Gainesville | Florida | 32610 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Worcester | Massachusetts | 01655 | — |
| Research Site | Omaha | Nebraska | 68130 | — |
| Research Site | New Brunswick | New Jersey | 08903 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | New York | New York | 10032 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Memphis | Tennessee | 38163 | — |
| Research Site | Dallas | Texas | 75230 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02211131, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2023 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02211131 live on ClinicalTrials.gov.